Search: onr:"swepub:oai:DiVA.org:uu-72916" >
Common VKORC1 and G...
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
-
- Wadelius, Mia (author)
- Uppsala universitet,Klinisk farmakogenomik och osteoporos
-
Chen, L.Y. (author)
-
Downes, K. (author)
-
show more...
-
Ghori, J. (author)
-
Hunt, S. (author)
-
- Eriksson, Niclas (author)
- Uppsala universitet,Klinisk farmakologi
-
- Wallerman, Ola (author)
- Uppsala universitet,Institutionen för genetik och patologi,Systems genomics
-
- Melhus, Håkan (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Osteoporos
-
- Wadelius, Claes (author)
- Uppsala universitet,Institutionen för genetik och patologi,Systems genomics
-
Bentley, D. (author)
-
Deloukas, P. (author)
-
show less...
-
(creator_code:org_t)
- 2005-05-10
- 2005
- English.
-
In: The Pharmacogenomics Journal. - : Springer Science and Business Media LLC. - 1470-269X .- 1473-1150. ; 5:4, s. 262-70
- Related links:
-
http://www.ncbi.nlm....
-
show more...
-
https://www.nature.c...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- We report a novel combination of factors that explains almost 60% of variable response to warfarin. Warfarin is a widely used anticoagulant, which acts through interference with vitamin K epoxide reductase that is encoded by VKORC1. In the next step of the vitamin K cycle, gamma-glutamyl carboxylase encoded by GGCX uses reduced vitamin K to activate clotting factors. We genotyped 201 warfarin-treated patients for common polymorphisms in VKORC1 and GGCX. All the five VKORC1 single-nucleotide polymorphisms covary significantly with warfarin dose, and explain 29-30% of variance in dose. Thus, VKORC1 has a larger impact than cytochrome P450 2C9, which explains 12% of variance in dose. In addition, one GGCX SNP showed a small but significant effect on warfarin dose. Incorrect dosage, especially during the initial phase of treatment, carries a high risk of either severe bleeding or failure to prevent thromboembolism. Genotype-based dose predictions may in future enable personalised drug treatment from the start of warfarin therapy.The Pharmacogenomics Journal advance online publication, 10 May 2005; doi:10.1038/sj.tpj.6500313.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- warfarin
- VKORC1
- CYP2C9
- pharmacogenomics
- GGCX
- Pharmacological research
- Farmakologisk forskning
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Wadelius, Mia
-
Chen, L.Y.
-
Downes, K.
-
Ghori, J.
-
Hunt, S.
-
Eriksson, Niclas
-
show more...
-
Wallerman, Ola
-
Melhus, Håkan
-
Wadelius, Claes
-
Bentley, D.
-
Deloukas, P.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmacology and ...
- Articles in the publication
-
The Pharmacogeno ...
- By the university
-
Uppsala University